Intracrinology of breast microenvironment: Hormonal status in nipple aspirate fluid and its relationship to breast cancer

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 5, 2009, Pages 493-505

  Mannello, Ferdinando ^a   Medda, Virginia ^a   Smaniotto, Alessandra ^a   Tonti, Gaetana A ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Breast cancer; Diagnosis; Hormones; Intracrinology; Nipple aspirate fluid; Prognosis; Tumor marker

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CALCITONIN; CATHEPSIN D; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN; ESTROGEN SULFOTRANSFERASE; ESTRONE; ESTRONE SULFATE; INTERLEUKIN 6; LEPTIN; ORAL CONTRACEPTIVE AGENT; PRASTERONE; PROGESTERONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN PS2; SEX HORMONE BINDING GLOBULIN; STEROID HORMONE; STERYL SULFATASE; TESTOSTERONE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER;

APOPTOSIS; BREAST CANCER; CANCER RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; EPITHELIUM CELL; FEMALE; HORMONAL REGULATION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; MENSTRUAL CYCLE; MICROENVIRONMENT; NIPPLE ASPIRATION; PATHOPHYSIOLOGY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; SAFETY;

EID: 70450054558     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.28     Document Type: Review

References (79)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr. Relat. Cancer 12(2), 185-213 (2005). •• Brilliant overview clarifying the advantages and drawbacks of breast cell- and tissue-collection methods; useful for improvement of diagnostic accuracy and risk assesment of breast cancer.
3. Gralow J, Ozols RF, Bajorin DF et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J. Clin. Oncol. 26(2), 313-325 (2008).
4. Sauter ER. Analysis of nipple aspirate fluid for diagnosis of breast cancer: an alternative to invasive biopsy. Expert Rev. Mol. Diagn. 5(6), 873-881 (2005). • Well described review of potential utility of nipple aspirate fluid (NAF) as a new tool for early detection of breast cancer.
5. Mannello F, Tonti GA, Canestrari F. Nutrients and nipple aspirate fluid composition: the breast microenvironment regulates protein expression and cancer aetiology. Genes Nutr. 3, 77-85 (2008). • Updated review of the effects of diet in NAF microenvironment biomolecular composition.
6. Sauter ER, Ross E, Daly M et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br. J. Cancer 76(4), 494-501 (1997). (Pubitemid 27331215)
7. Keynes G. Chronic mastitis. Br. J. Surgery 11, 89-121 (1923).
8. Petrakis NL. Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res. Treat. 8(1), 7-19 (1986). • First review on the epidemiology and biocomposition of NAF.
9. Petrakis NL. Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid. Cancer Epidemiol. Biomarkers Prev. 2(1), 3-10 (1993).
10. Dua RS, Isacke CM, Gui GP. The intraductal approach to breast cancer biomarker discovery. J. Clin. Oncol. 24(7), 1209-1216 (2006). • Comprehensive review highlighting the potential applications of NAF studies.
11. Adair FE , Bagg HJ. Breast stasis as the cause of mammary cancer. Int. Clin. 4, 19-26 (1925). •• Milestone hypothesis about the NAF formation mechanisms and its relationship to cancer.
12. Sartorius OW. Breast fluid cells help in early cancer detection. JAMA 224, 823-827 (1973).
13. Petrakis NL, Mason L, Lee R, Sugimoto B, Pawson S, Catchpool F. Association of race, age, menopausal status, and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration. J. Natl Cancer Inst. 54(4), 829-834 (1975).
14. Sartorius OW. The biochemistry of breast cyst fluids and duct secretions. Breast Cancer Res. Treat. 35(3), 255-266 (1995).
15. Sauter ER, Ehya H, Babb J et al. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. Br. J. Cancer 81(7), 1222-1227 (1999).
16. Mannello F. Analysis of the intraductal microenvironment for the early diagnosis of breast cancer: identification of biomarkers in nipple-aspirate fluids. Expert Opin. Med. Diagn. 2(11), 1221-1231 (2008). • Overview of morphologic and biomolecular studies performed on NAF.
17. Mannello F, Tonti GA, Papa S. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Res. Treat. 97(2), 115-129 (2006). •• Detailed state-of-the-art of 30 years of morphological, biochemical, hormonal and clinical findings on breast cyst fluid collected from gross cystic breast disease-affected women.
18. Malatesta M, Mannello F, Bianchi G, Sebastiani M, Gazzanelli G. Biochemical and ultrastructural features of human milk and nipple aspirate fluids. J. Clin. Lab. Anal. 14(6), 330-335 (2000).
19. Petrakis NL, Barnes S, King EB et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 5(10), 785-794 (1996). (Pubitemid 26346277)
20. Sauter ER, Winn JN, Dale PS, Wagner-Mann C. Nipple aspirate fluid color is associated with breast cancer. Cancer Detect. Prev. 30(4), 322-328 (2006). (Pubitemid 44402904)
21. Kato I, Ren J, Heilbrun LK, Djuric Z. Intra- and inter-individual variability in measurements of biomarkers for oxidative damage in vivo: NUTRITION and Breast Health Study. Biomarkers 11(2), 143-152 (2006). (Pubitemid 43772011)
22. Zhang L, Shao ZM, Beatty P et al. The use of oxytocin in nipple fluid aspiration. Breast J. 9(4), 266-268 (2003). (Pubitemid 36927403)
23. Suijkerbuijk KP, van der WE, van Diest PJ. Oxytocin: bringing magic into nipple aspiration. Ann. Oncol. 18(10), 1743-1744 (2007).
24. Suijkerbuijk KP, van der WE, Vooijs M, van Diest PJ. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 75(2), 149-152 (2008).
25. Mannello F, Medda V, Tonti GA. Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev. Proteomics 6(1), 43-60 (2009). •• Updated review of NAF protein composition.
26. Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detect. Prev. 31(1), 50-58 (2007). (Pubitemid 46367450)
27. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 13(2), 129-136 (2006).
28. Suzuki T, Miki Y, Moriya T et al. In situ production of sex steroids in human breast carcinoma. Med. Mol. Morphol. 40(3), 121-127 (2007). (Pubitemid 47415942)
29. Sasano H, Suzuki T, Harada N. From endocrinology to intracrinology. Endocr. Pathol. 9(1), 9-20 (1998).
30. Li J, Zhao J, Yu X et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 11(23), 8312-8320 (2005). (Pubitemid 41746942)
31. Spicer DV, Pike MC. The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol. 31(2), 167-174 (1992).
32. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15(1), 17-35 (1993). (Pubitemid 23269068)
33. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113), 1393-1396 (1998).
34. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl Cancer Inst. 87(3), 190-197 (1995).
35. Sturgeon SR, Potischman N, Malone KE et al. Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes Control 15(1), 45-53 (2004). (Pubitemid 38339971)
36. Suzuki T, Miki Y, Ohuchi N, Sasano H. Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 15(4), 270-277 (2008).
37. Chatterton RT Jr, Geiger AS, Gann PH, Khan SA. Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J. Steroid Biochem. Mol. Biol. 86(2), 159-166 (2003).
38. Wynder EL, Hill P. Prolactin, oestrogen, and lipids in breast fluid. Lancet 2(8043), 840-842 (1977). •• Initial evidence of the hormone content in NAF. (Pubitemid 8199527)
39. Miller WR, Hawkins RA, Creel RJ, Forrest AP. Oestrogen in breast fluid. Lancet 2(8049), 1179 (1977).
40. Wynder EL, Hill P, Laakso K, Littner R, Kettunen K. Breast secretion in Finnish women: a metabolic epidemiologic study. Cancer 47(6), 1444-1450 (1981). (Pubitemid 11090516)
41. Mannello F, Tonti GA, Medda V, Pederzoli A, Sauter ER. Increased shedding of soluble fragments of p-cadherin in nipple aspirate fluids from women with breast cancer. Cancer Sci. 99(11), 2160-2169 (2008).
42. Mannello F, Tonti GA, Qin W, Zhu W, Sauter ER. Do nipple aspirate fluid epithelial cells and their morphology predict breast cancer development? Breast Cancer Res. Treat. 102(1), 125-127 (2007). • Working hypothesis on the role of adhesion molecules in the cellular mechanisms of NAF formation. (Pubitemid 46294963)
43. Petrakis NL, Wrensch MR, Ernster VL et al. Influence of pregnancy and lactation on serum and breast fluid estrogen levels: implications for breast cancer risk. Int. J. Cancer 40(5), 587-591 (1987).
44. Ernster VL, Wrensch MR, Petrakis NL et al. Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J. Natl Cancer Inst. 79(5), 949-960 (1987).
45. King EB, Chew KL, Petrakis NL, Ernster VL. Nipple aspirate cytology for the study of breast cancer precursors. J. Natl Cancer Inst. 71(6), 1115-1121 (1983).
46. Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol. Biomarkers Prev. 14(2), 324-328 (2005). (Pubitemid 40270092)
47. Wrensch MR, Petrakis NL, Miike R et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J. Natl Cancer Inst. 93(23), 1791-1798 (2001). (Pubitemid 33150451)
48. Rose DP. Hormones in breast fluid. Breast Cancer Res. Treat. 8(1), 25-28 (1986).
49. Hill P, Garbaczewski L, Wynder EL. Testosterone in breast fluid. Lancet 1(8327), 761 (1983).
50. Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH. Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol. Biomarkers Prev. 13(6), 928-935 (2004).
51. Rose DP, Berke B, Cohen LA, Lahti H. A comparison of serum and breast duct fluid-immunoassayable prolactin and growth hormone with bioassayable lactogenic hormones in healthy women and patients with cystic breast disease. Cancer 60(11), 2761-2765 (1987). (Pubitemid 17161809)
52. Gann PH, Geiger AS, Helenowski IB, Vonesh EF, Chatterton RT. Estrogen and progesterone levels in nipple aspirate fluid of healthy premenopausal women: relationship to steroid precursors and response proteins. Cancer Epidemiol. Biomarkers Prev. 15(1), 39-44 (2006).
53. Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH. Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J. Clin. Endocrinol. Metab. 90(3), 1686-1691 (2005). • Intriguing report on the physiopathological relevance of NAF hormone levels as potential breast cancer risk markers.
54. Khan SA, Bhandare D, Chatterton RT Jr. The local hormonal environment and related biomarkers in the normal breast. Endocr. Relat. Cancer 12(3), 497-510 (2005). • Interesting overview integrating informations about cellular and NAF biomarkers of hormone action on the breast to identify breast cancer candidate biomarkers. (Pubitemid 41482990)
55. Sasano H, Nagasaki S, Miki Y, Suzuki T. New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase. Ann. NY Acad. Sci. 1155, 76-79 (2009). • Updated review on inhibition pathways as endocrine treatment of BC.
56. Miller WR, Humeniuk V, Kelly RW. Dehydroepiandrosterone sulphate in breast secretions. J. Steroid Biochem. 13(2), 145-151 (1980).
57. Miller WR, Humeniuk V, Forrest AP. Factors affecting dehydroepiandrosterone sulphate levels in human breast secretions. Breast Cancer Res. Treat. 1(3), 267-272 (1981).
58. Boccuzzi G, Brignardello E, Massobrio M, Bonino L. Breast duct fluid dehydroepiandrosterone sulphate in fibrocystic disease. Eur. J. Cancer Clin. Oncol. 23(8), 1099-1102 (1987). (Pubitemid 17112469)
59. Kuhn-Velten WN. Intracrinology and the local enzymatic control of hormone distribution and metabolism: dehydroepiandrosterone does not just act as a prohormone for androgens and estrogens. Eur. J. Clin. Invest 30(Suppl. 3), 34-38 (2000).
60. Perel E , Killinger DW. The metabolism of androstenedione and testosterone to C19 metabolites in normal breast, breast carcinoma and benign prostatic hypertrophy tissue. J. Steroid Biochem. 19(2), 1135-1139 (1983).
61. Sauter ER, Tichansky DS, Chervoneva I, Diamandis EP. Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. Environ. Health Perspect. 110(3), 241-246 (2002). (Pubitemid 34257189)
62. Rose DP, Boyar AP, Kettunen K. Diet, serum, breast fluid growth hormone, and prolactin levels in normal premenopausal Finnish and American women. Nutr. Cancer 11(3), 179-187 (1988). (Pubitemid 18172958)
63. Rose DP. Hormones and growth factors in nipple aspirates from normal women and benign breast disease patients. Cancer Detect. Prev. 16(1), 43-51 (1992).
64. Harding C, Osundeko O, Tetlow L, Faragher EB, Howell A, Bundred NJ. Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. Br. J. Cancer 82(2), 354-360 (2000). (Pubitemid 30045381)
65. Eskelinen M, Kataja V, Hamalainen E, Kosma VM. Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study. Anticancer Res. 19(4C), 3463-3467 (1999). (Pubitemid 30000204)
66. Mitchell G, Sibley PE, Wilson AP, Sauter E, A'Hern R, Eeles RA. Prostate-specific antigen in nipple aspiration fluid: menstrual cycle variability and correlation with serum prostate-specific antigen. Tumour Biol. 23(5), 287-297 (2002). (Pubitemid 36302486)
67. Sauter ER, Babb J, Daly M et al. Prostate-specific antigen production in the female breast: association with progesterone. Cancer Epidemiol. Biomarkers Prev. 7(4), 315-320 (1998). (Pubitemid 28354143)
68. Sauter ER, Klein G, Wagner-Mann C, Diamandis EP. Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. Cancer Detect. Prev. 28(1), 27-31 (2004). (Pubitemid 39403830)
69. Mannello F, Malatesta M, Sebastiani M, Battistelli S, Gazzanelli G. Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids. Clin. Chem. 45(12), 2263-2266 (1999).
70. Sauter ER, Lininger J, Magklara A, Hewett JE, Diamandis EP. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int. J. Cancer 108(4), 588-591 (2004). (Pubitemid 38036660)
71. Zhao Y, Verselis SJ, Klar N et al. Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts. J. Clin. Oncol. 19(5), 1462-1467 (2001). (Pubitemid 32202554)
72. Mannello F, Gazzanelli G. Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res. 3(4), 238-243 (2001). (Pubitemid 32631703)
73. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta 1654(2), 123-143 (2004).
74. Jansson A. 17b-hydroxysteroid dehydrogenase enzymes and breast cancer. J. Steroid Biochem. Mol. Biol. 114(1-2), 64-67 (2009). •• Interesting overview on the estrogen-metabolizing enzymes in the normal breast and the intratumoral synthesis of sex steroids in BC.
75. King BL, Love SM. The intraductal approach to the breast: raison d'etre. Breast Cancer Res. 8(2), 206 (2006).
76. Rochman S, Mills D, Kim J, Kuerer H, Love S. State of the science and the intraductal approach for breast cancer: proceedings summary of the Sixth International Symposium on the Intraductal Approach to Breast Cancer, Santa Monica, California, 19-21 February 2009. BMC Proc. 3(Suppl. 5), I1 (2009). • Highlights on future perspective of intraductal approaches.
77. Sauter ER, Garofalo C, Hewett J, Hewett JE, Morelli C, Surmacz E. Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer. Horm. Metab. Res. 36(5), 336-340 (2004). (Pubitemid 38703795)
78. Connolly JM , Rose DP. Epidermal growth factor-like proteins in breast fluid and human milk. Life Sci. 42(18), 1751-1756 (1988).
79. Black MH, Magklara A, Obiezu C et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br. J. Cancer 82(2), 361-367 (2000). (Pubitemid 30045382)